44 results about "Multiple myeloma" patented technology

The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and / or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.

The application discloses a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative and a synthesis method and application thereof, and relates to a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative which is a compound with the following general formula (I): wherein R1 is selected from,,,,,,,,, and R2 is selected from,,, and. The compound can significantly inhibit the proliferation of leukemia, multiple myeloma, lymphoma, breast cancer, liver cancer and the like at a low dose (nanomole), can effectively degrade IKZF1, IKZF3, BRD4, GSPT1 and CK1 alpha, and has the prospect of being developed into an anti-tumor drug. The application solves the problem that the existing malignant hematological disease treatment drugs have a high safety risk.

The application provides a nanobody targeting human transmembrane activator and calcium modulator and cyclophilin interactor (TACI) and an application thereof, and the antibody is derived from a llama heavy chain antibody variable region. The anti-TACI single-domain antibody NB38 can specifically bind to human TACI with high affinity, can recognize a recombinant TACI protein, can also recognize a TACI with a natural conformation on a cell surface, and can partially block a BAFF / APRIL signal pathway. Based on the nanobody, the application constructs a fusion protein, a chimeric antigen receptor, an effector cell expressing the chimeric antigen receptor, and a double-specific cell linker and other genetically engineered forms. The nanobody can be further extended into a drug coupling form. The product of the application can be used for mediating directional recognition and killing of TACI positive cells, and can be used as a supplement and expansion of BCMA targeted therapy, and provides a new candidate technical scheme for targeted therapy of multiple myeloma and other TACI related diseases.

The present invention relates to use of a pharmaceutical composition for multiple myeloma containing 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidine-5-yl)oxy]-N,N-di(propan-2-yl)benzamide.

The present disclosure provides methods of treating multiple myeloma in a subject with a Bcl-2 inhibitor, in particularly 2- ( (1H-pyrrolo [2, 3-b] pyridin-5-yl) oxy) -N- ( (4- ( ( ( (1r, 4r) -4-hydroxy-4-methylcyclohexyl) methyl) amino) -3-nitrophenyl) sulfonyl) -4- (2- ( (S) -2- (2-isopropylphenyl) pyrrolidin-1-yl) -7-azaspiro [3.5] nonan-7-yl) benzamide or a pharmaceutically acceptable salt thereof, or in combination with dexamethasone.

Provided is a composition which can be a lyophilized preparation solution or a lyophilized powder preparation. The composition comprises a multispecific antibody, a surfactant, a buffer system, and a stabilizer / osmotic pressure regulator. Further provided are a preparation method for the composition and use of the composition, for example, use in treating tumors, especially multiple myeloma.

Provided herein are methods and uses of combination therapies involving a GPRC5D-targeted cell therapy comprising a chimeric antigen receptor (CAR) containing an extracellular antigen binding domain that binds to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and a combination agent, e.g., a bispecific antibody, for treating a subject having a cancer, such as multiple myeloma, as well as related methods, uses, and articles of manufacture.

Embodiments of the invention relate to methods of treating multiple myeloma in a subject in need thereof, the method comprising administering to the subject a BCMAxCD3 bispecific antibody on a monthly dosing schedule.

The present invention relates to the use of a pharmaceutical composition against multiple myeloma, the composition comprising 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide.

The application discloses a risk assessment system for cross matching difficulty, and relates to the technical field of clinical medical examination and blood transfusion management. The system comprises a data input module, a risk calculation module, a risk stratification module and a result output and suggestion module. The data input module obtains key information of a patient, including irregular red blood cell antibody screening results, multiple myeloma diagnosis, hematology department medical history, age of 60 years or older, pregnancy-related disease state and blood type identification difficulty; the risk calculation module adopts a preset scoring algorithm to assign weights to each factor and calculate a total risk score; the risk stratification module divides the patient into three grades of low risk, medium risk and high risk; and the result output module provides a differentiated clinical management path corresponding to the risk grade. The application realizes early warning of cross matching difficulty through quantitative assessment, can optimize the efficiency of the blood transfusion process and reduce clinical risk, has good prediction performance (AUC=0.819) and a high negative predictive value (93.7%).

The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

Provided herein are methods of treating a subject who has multiple myeloma and has received an initial therapy, including a stem cell transplantation. Infusions of chimeric antigen receptor (CAR)-T cells comprising a BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 x 105 to 5.0 x 106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.

This article provides methods and uses relating to GPRC5D-targeted cell therapy and combination therapies, such as immunomodulatory compounds, for treating subjects with cancers such as multiple myeloma, wherein the GPRC5D-targeted cell therapy comprises a chimeric antigen receptor (CAR) containing an extracellular antigen-binding domain that binds to a G protein-coupled receptor class C group 5 member D (GPRC5D); and related methods, uses, and articles thereof.

This invention discloses a method and application for constructing personalized organoids for multiple myeloma based on stiffness gradient regulation, belonging to the field of biomedical technology. The method includes the following steps: S1: mixing patient bone marrow plasma with a calcium-containing crosslinking agent to form a gelatable precursor; S2: combining the gelatable precursor with a three-dimensional gelatin scaffold having a stiffness gradient (Young's modulus of 25-50 kPa) to construct a three-dimensional microenvironment simulating the stiffness gradient of bone marrow; S3: gelling the precursor to form a hydrogel-scaffold composite system encapsulating target cells; S4: seeding vascular endothelial cells onto the surface of the composite system to simulate a vascular niche structure. The organoid model for multiple myeloma constructed by this invention, based on the patient's autologous bone marrow plasma and possessing stiffness gradient characteristics, can effectively simulate the bone marrow mechanical microenvironment and preserve key components of the tumor microenvironment, supporting the long-term growth of primary tumor cells and improving the accuracy of drug sensitivity prediction.

This invention relates to the field of traditional Chinese medicine composition technology, and particularly to an oral traditional Chinese medicine composition for treating multiple myeloma and its preparation method. It comprises the following components in parts by weight: Bupleurum chinense 10-12 parts, Cyperus rotundus 8-10 parts, Curcuma longa 8-10 parts, Oroxylum indicum 5-6 parts, Angelica sinensis 8-10 parts, Paeonia lactiflora 8-10 parts, Atractylodes macrocephala 10-12 parts, Poria cocos 10-12 parts, Codonopsis pilosula 8-10 parts, Glycyrrhiza uralensis (processed) 5-6 parts, Agrimonia pilosa 6-8 parts, Bambusa textilis 8-10 parts, Mentha haplocalyx 4-6 parts, and Zingiber officinale 4-6 parts. The composition provided by this invention not only directly inhibits the growth of myeloma cells, but also comprehensively improves the survival prognosis of model animals by regulating liver and spleen function, improving immune status, and reducing phlegm-heat and blood stasis. It provides a stable, safe, and easily promoted oral traditional Chinese medicine preparation for the clinical treatment of multiple myeloma.

Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.

This application discloses a single-domain antibody targeting GPRC5D and related materials and applications, belonging to the field of biomedical technology. The technical problem this application aims to solve is how to achieve sensitive and efficient detection and / or precise targeted therapy for GPRC5D. To solve this technical problem, this application provides a single-domain antibody with amino acid sequences of CDR1, CDR2, and CDR3 as shown in positions 31-35, 50-66, and 99-105 of SEQ ID NO:1, respectively. This single-domain antibody has a high affinity for the GPRC5D protein and can specifically recognize and target GPRC5D-positive cells. By binding to radionuclides, anticancer agents, or contrast agents, this single-domain antibody can be developed into a targeted imaging agent for multiple myeloma, an immunotherapy drug (vaccine), or a single-domain antibody-drug conjugate, which can be used for early tumor diagnosis, immune monitoring, and targeted therapy.

The application provides application of a KRAS inhibitor and an AKR inhibitor in resisting drug resistance of tumor cells, and the KRAS inhibitor and the aldehyde-ketone reductase inhibitor can be combined to be used for treating various cancers, especially as a compound medicine for treating malignant tumors such as pancreatic cancer, colorectal cancer, multiple myeloma, lung cancer and melanoma. The compound medicine can greatly improve the treatment effect of the existing KRAS inhibitor, can reverse the drug resistance of the chemotherapy medicine, can reduce the dosage of the KRAS inhibitor in the anti-tumor treatment, can not only avoid the increase of the dosage of the KRAS inhibitor due to the drug resistance, but also can correspondingly reduce the risk of the increase of the toxic side effect due to the increase of the dosage after the drug resistance, and has positive pharmaceutical value and wide social significance. The application further provides a compound anti-tumor medicine which comprises an aldehyde-ketone reductase inhibitor, a KRAS inhibitor and a pharmaceutically acceptable carrier.

This invention belongs to the field of heterocyclic compound technology, specifically relating to a protein hydrolysis-targeted chimera for the treatment of multiple myeloma, its preparation method, and its application. Compounds 2, 3, and HATU are dissolved in THF, then DIPEA is added and the reaction is stirred. Water is added to terminate the reaction, followed by extraction, washing, drying, and column chromatography to obtain product 4. Under argon protection, product 4 is dissolved in dichloromethane, then trifluoroacetic acid is added and the reaction is carried out. Toluene is added, and the mixture is distilled under reduced pressure to obtain product 5. Product 5, compound 6, HATU, and DIPEA are dissolved in THF and the reaction is stirred. Water is added to terminate the reaction, followed by extraction, washing, drying, and column chromatography to obtain the protein hydrolysis-targeted chimera for the treatment of multiple myeloma. The protein hydrolysis-targeted chimera for the treatment of multiple myeloma in this invention exhibits significant anti-proliferative activity against RPMI-8266 multiple myeloma cells. The preparation process is simple and suitable for industrial production.

This invention relates to the field of biomedical technology, specifically to the application of schisandrin A in the preparation of drugs for treating multiple myeloma. The schisandrin A (SchA) provided by this invention exerts its therapeutic effect on multiple myeloma by synergistically inducing apoptosis and mitophagy in multiple myeloma cells. The structural formula of the schisandrin A is as follows:

Embodiments of the present invention relate to a method for treating subjects requiring treatment for multiple myeloma, and include administering a BCMAxCD3 bispecific antibody to the subjects on a bi-weekly schedule.

A 4-carboxyamino isoindoline-1,3-dione compound represented by formula (I), or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate (e.g. hydrate) thereof, or a clathrate thereof, or a racemate thereof, or an isotopically-labeled material thereof, or a nitroxide thereof; and pharmaceutical compositions and uses thereof. The compound has good anti-multiple myeloma activity, and can effectively treat and / or prevent the growth of multiple myeloma.

The application provides a method for defluorocyclization reaction of fluoroalkyl peroxide and benzylamine under the promotion of triethylenediamine and potassium phosphate, and synthesizes a series of fluoroalkyl pyridine compounds. 3 The reaction realizes precise synthesis of the fluoroalkyl-substituted pyridine compound by selectively activating six C(sp )‑F bonds of three carbon sites on the fluoroalkyl chain, has the characteristics of mild conditions, good functional group tolerance, simple post-treatment, green steps, low pollution and high economic benefits, and the obtained compound shows certain anti-human multiple myeloma cell (U266) activity, and can be used for preparing an active inhibitor for resisting human multiple myeloma cells.

The present application belongs to the technical field of molecular diagnosis, and relates to a gene combination for evaluating prognosis of multiple myeloma and PRMM risk and a method for evaluating the same. The gene combination is a combination of MCM3, FABP5, MIR4435-2HG, FH, HELLS, CCDC34, RPS6KA1, FEN1 and OPN3 genes. Detection with the gene combination as a biomarker can specifically and accurately evaluate the prognosis of a multiple myeloma patient, especially the death risk, and the risk of the multiple myeloma patient being a primary refractory multiple myeloma according to the detection result.

A composition is provided, which can be a lyophilized preparation liquid or a lyophilized powder formulation. The composition comprises a multispecific antibody, a surfactant, a buffer system and a stabilizer / osmotic pressure regulator. Also provided are methods of preparing the composition and uses thereof, for example in the treatment of tumors, in particular multiple myeloma.

The present application provides a set of complete innovative technical solutions from target discovery to treatment intervention for the immune escape and drug resistance recurrence problems existing in the clinical treatment of multiple myeloma (MM). It is found that Siglec7 is mainly highly expressed on the surface of NK cells, and the proportion and expression intensity of Siglec7 positive NK cells are significantly higher than those of complete remission and non-tumor controls; further, Siglec7 monoclonal antibody is prepared, and when the anti-Siglec7+CD38 monoclonal antibody (such as daratumumab) is used, a significant synergistic anti-tumor effect can be produced in vitro and in vivo. The technical solution completely constructs the research and development chain of "marker discovery-target verification-drug development-treatment application", and provides a new target, specific antibody drug and innovative combined drug regimen for the precise diagnosis, prognosis and especially immunotherapy of refractory and relapsed patients with multiple myeloma, which has great clinical transformation value and market prospect.

1. Name of the designed product: waist supporter (for multiple myeloma patients). 2. Use of the designed product: used as a waist supporter for supporting the waist. 3. Design points of the designed product: in shape. 4. Picture or photograph best indicating the design points: perspective view.

The present invention discloses a compound represented by the following chemical formula (I) or a pharmaceutically acceptable salt thereof. The present invention also discloses a method for preparing said compound and the use of said compound in the prevention and / or treatment of cancer or tumor-related diseases, particularly breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colorectal cancer, liver cancer, pancreatic cancer, human glioma, etc. The compound of the present invention is expected to be developed as a next-generation anticancer agent.

A 4-carbonylamino isoindolin-1-one compound represented by formula (I), or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate (e.g. hydrate) thereof, or a clathrate thereof, or a racemate thereof, or an isotopically-labeled material thereof, or a nitroxide thereof; and pharmaceutical compositions and uses thereof. The compound has good anti-multiple myeloma activity, and can effectively treat and / or prevent the growth and reproduction of multiple myeloma.

The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLKI, CLK2, CLK3, CLK4, and HASPIN. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, and HASPIN, such that the one or more kinases is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the one or more kinases. The bifunctional compounds serve as therapeutics for the treatment of Alzheimer's disease, down syndrome, diabetes, an autoimmune disease, an inflammatory disorder (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer), a viral infection (e.g., SARS-COV-2 infection (e.g., COVID-19)), and other diseases.